The Moving Average Convergence Divergence (MACD) for CSPCY turned positive on December 23, 2024. Looking at past instances where CSPCY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where CSPCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CSPCY advanced for three days, in of 192 cases, the price rose further within the following month. The odds of a continued upward trend are .
CSPCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on December 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CSPCY as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CSPCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CSPCY entered a downward trend on December 18, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.293) is normal, around the industry mean (5.632). P/E Ratio (11.338) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (2.341) is also within normal values, averaging (3.004). Dividend Yield (0.033) settles around the average of (0.164) among similar stocks. P/S Ratio (2.228) is also within normal values, averaging (3.643).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CSPCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CSPCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.
Industry PharmaceuticalsMajor
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GTHCX | 17.32 | 0.14 | +0.81% |
Invesco Health Care C | |||
AFEGX | 54.00 | 0.42 | +0.78% |
American Century Large Cap Equity G | |||
LCILX | 26.39 | 0.15 | +0.57% |
ClearBridge Sustainability Leaders IS | |||
FIVCX | 34.33 | 0.10 | +0.29% |
Delaware Opportunity C | |||
DFMLX | 37.56 | 0.03 | +0.08% |
DF Dent Midcap Growth Institutional Plus |
A.I.dvisor tells us that CSPCY and CHJTF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSPCY and CHJTF's prices will move in lockstep.
Ticker / NAME | Correlation To CSPCY | 1D Price Change % | ||
---|---|---|---|---|
CSPCY | 100% | +0.83% | ||
CHJTF - CSPCY | 23% Poorly correlated | -0.77% | ||
DSNKY - CSPCY | 16% Poorly correlated | -0.78% | ||
BAYZF - CSPCY | 12% Poorly correlated | +0.23% | ||
DSKYF - CSPCY | 5% Poorly correlated | -1.14% | ||
CMOPF - CSPCY | 4% Poorly correlated | N/A | ||
More |